Sutro is an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), with STRO-006, a differentiated integrin beta-6 ADC expected to enter clinical development in 2026 aimed at multiple solid tumors, and ongoing collaborations with Ipsen for STRO-003, a ROR1 ADC, and with Astellas for dual-payload immunostimulatory ADCs (iADCs).
Cyborg Score Rationale
With a market cap of $256M and trailing twelve-month revenue of $106M, Sutro shows modest commercial progress. However, the company reduced headcount by nearly 50 percent with changes expected to be substantially complete by the end of 2025, indicating significant operational restructuring and execution risk. The team has been reduced from approximately 350 to about 130 employees.
Top Insights
STRO-004, its potential best-in-class Tissue Factor ADC, has now entered clinical development
The company is working to accelerate its dual-payload ADC program, with an IND submission now targeted for 2026/2027
In February 2026, Sutro announced an underwritten offering of 7,868,383 shares at $13.98 per share for approximately $110 million in gross proceeds
Cost reductions from restructuring combined with refocused clinical development priorities give the Company an expected cash runway into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations